News Archive

Less complex heart patients may benefit, but not without risk

In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths,

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the

New research shows COVID-19 patients have a higher likelihood of heart failure post-discharge

Pulmonary rehabilitation is an important evidenced-based treatment to improve health and quality of life for people living with Chronic Obstructive Pulmonary Disease (COPD). Now, new research from the Duke Clinical Research Institute has shown that the benefits of pulmonary rehabilitation are likely to extend beyond the patient to reduce costs for the health care system as well – with an estimated savings of more than $5,000 per patient.

If you want to change patient and provider behavior to improve a patient’s health, will an informational mailer make a difference?

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health with support from the Duke Clinical Research Institute shows that treating adults hospitalized with COVID-19 with infliximab or abatacept – drugs widely used to treat certain autoimmune diseases – substantially improved clinical status and reduced deaths.

A recent paper from Duke Clinical Research Institute (DCRI) faculty on behalf of the American Gastroenterological Association (AGA) provides new tools for health care providers treating patients wi

A new study set out to determine the prevalence of tPA declination in a nationwide registry of acute ischemic stroke (AIS) patients and to investigate differences in declination by race-ethnicity. The results appear in a paper in the February 28 issue of Neurology entitled ‘Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke.’

A recent publication reports on an analysis of how study-specific fitness-for-use was addressed amongst pragmatic clinical trials that utilize real-world data (RWD), and makes recommendations to de